French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum ...

China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines (SHA: 688235), ...

The US Food and Drug Administration (FDA) has taken the radical move of publishing more than 200 decision letters, known as ...

The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...

US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI ...

The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line ...

US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today ...

BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene (SHA: 688235) - has announced that the ...

The US Food and Drug Administration (FDA) has accepted the supplemental new drug application (sNDA) for Inqovi (decitabine ...

French biotech Inventiva has changed up its executive team as it continues to bet on experimental MASH therapy lanifibranor, ...

Japanese authorities are putting Eisai (TSE: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer ...